Delcath Systems Inc (DCTH)

[staccani]

A company with 2 ph3's in cancer and $60M market cap cannot go bankrupt. The BOD just need to negotiate a deal with an interested BP (any of them would be willing to pay a few hundreds M USD). After all Liver Cancer has not had any new treatment approved for 10 years despite prognosis being dismal, whilst Chemosat is very promising and this info is coming from doctors in the field not the company (this tells you everything about how inept mngt is)